Contact Information: INVESTOR CONTACT: Debbie Bailey 631-444-8090 fax: 631-444-8848 MEDIA CONTACT: Janice Meraglia 631-444-6293 fax 631-444-8848 FCMN Contact: Web site: http://www.ADNAS.com
Applied DNA Sciences Builds Healthcare Security Momentum
| Source: Applied DNA Sciences, Inc.
STONY BROOK, NY--(Marketwire - March 3, 2009) - Applied DNA Sciences, Inc. (OTCBB : APDN ), a
provider of DNA security solutions, announced today that it is increasing
its focus on security offerings to the Healthcare industry. The company has
steadily added to its patent portfolio and many of its issued and pending
patents can protect the Personal Care, Pharmaceutics, Medical Device and
Biotechnology industry verticals. Recently, there has been a surge in the
number of quotations being provided to healthcare companies for Applied
DNA's security markers and authentication services.
The healthcare industry is a highly lucrative target for counterfeiters who
have been known to introduce fake, harmful ingredients posing risk to
public health and safety on a global scale. APDN has two platforms, using
DNA that occurs naturally within a product or is added as extrinsic markers
that address the need for secure healthcare products.
Intrinsic DNA. Using its Biomaterial Genotyping™ platform, APDN has
recently proved its ability to verify the origin and authenticity of
naturally derived textiles such as cotton. The same approach can be used
to identify a pattern of native DNA content in biological drugs and in
naturally derived ingredients that are used in pharmaceuticals, personal
care formulations and nutritional supplements.
Extrinsic DNA. An alternative approach is to designate authenticity with an
extrinsic marker. APDN's SigNature® DNA markers are unique, botanically
derived markers that can not be copied and due to their enormous
variability, provide forensic proof of identity for brand protection.
SigNature DNA may be used in packaging and labels providing DNA security
ink on the printed surface, DNA-marked adhesive on the back of a label, as
well as protecting the serialization or barcode that is linked to a secure
database. SigNature DNA is a green, safe technology that can also be
incorporated in formulations of finished-goods.
For pharmaceuticals that are most vulnerable to counterfeiting and
diversion, APDN is soliciting a pharmaceutical partner who may be
interested in obtaining FDA approval for SigNature DNA to mark individual
pharmaceutical doses such as tablets and capsules, areas protected by
APDN's intellectual property. SigNature DNA is already in use to protect
the ingredients used in personal care. One customer, a large chemical
company called Rhodia, uses SigNature DNA to protect the bulk packaging for
a line of ingredients used in finished products for hair care and skin
care. APDN is now expanding its reach to clients who manufacture finished
goods.
Rapid screening. APDN has developed methods for associating SigNature DNA
to various optical and electronic reporters that permit front-end
screening. When combined with SigNature DNA, these reporters can not be
counterfeited or re-engineered. The combination allows for rapid, hand-held
authentication using "Level 1" devices that detect the reporter using the
optical, magnetic or electronic systems that are staples of the security
industry.
Layered security. When combined in a layered approach, SigNature DNA
elevates the security platforms developed by other security companies to a
forensic level. APDN has allied with security providers and members of the
Brand Protection Alliance to prototype secure packaging and labels for the
healthcare industry. The company is providing quotations to pharma and
personal care companies for DNA markers numbering in the hundreds of
thousands to the hundreds of millions.
"We can service the global need for complete security systems," commented
Dr. James A. Hayward, President & CEO, Applied DNA Sciences. "Elevating the
safety and reliability of healthcare is one of the most compelling
corollaries of our mission."
Global need for healthcare security. Every time a product changes hands,
the potential to introduce counterfeits increases. The World Health
Organization estimates that up to 10% of medicines worldwide are fake, as
are 50% of the illegal internet sales of pharmaceuticals. The Center for
Medicine in the Public Interest estimates that counterfeiting sales are
increasing approximately 12-16% annually, nearly twice the pace of
legitimate pharmaceuticals and could become a $75 billion industry by 2010.
Just in the EU, 1.6 million counterfeit cosmetic products were seized in
2006 To root out the problem of counterfeits and diverted products,
SigNature DNA can be used to trace and audit the movement of goods, from
inception to packing and shipping to the end consumer.
About Applied DNA Sciences
Applied DNA Sciences markets and sells DNA security solutions to protect
products, brands and intellectual property from counterfeiting and
diversion. Its patented technologies sold under SigNature DNA use DNA from
plants to mark and authenticate products in a unique manner that
essentially can not be copied. Applied DNA also provides BioMaterial
GenoTyping™ services by using genomic DNA present in natural materials
to identify the original source of DNA present in finished products. Both
platform technologies protect brands and products in a wide range of
industries and provide a forensic chain of evidence to enable enforcement
agencies to prosecute perpetrators. To learn more, go to www.adnas.com.
APDN's common stock is listed on the Over-The-Counter Bulletin Board under
the symbol "APDN."
The statements made by APDN may be forward-looking in nature and are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements describe APDN's future
plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many of which
are beyond the control of APDN. Actual results could differ materially from
those projected due to our short operating history, limited financial
resources, limited market acceptance, market competition and various other
factors detailed from time to time in APDN's SEC reports and filings,
including our Annual Report on Form 10-K, filed on December 16, 2008 and
our subsequent quarterly reports on Form 10-Q. APDN undertakes no
obligation to update publicly any forward-looking statements to reflect new
information, events or circumstances after the date hereof to reflect the
occurrence of unanticipated events.